Articles

Poll

Podcasts

Slideshows

Videos

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

As dermatology patients enter clinical visits with information from social media, online forums, and AI inquiries, clinicians are juggling new concerns.

How Online-Informed Patients Are Changing Dermatology Visits

Adults with difficult-to-treat psoriasis due to overweight or obesity saw notable benefits to both with concomitant ixekizumab and tirzepatide.

Ixekizumab + Tirzepatide Improves Psoriasis, Reduces Weight in Those with Obesity

Treatment-associated phenotype switching between psoriasis and atopic dermatitis was noted to be reproducible and bidirectional in real-world clinical settings.

Psoriasis-Atopic Dermatitis Phenotype Switching: New Real-World Data

Investigators released long-term data on long-term bimekizumab use in psoriasis suggest, demonstrating sustained efficacy through 4 years.

Long-Term Durability of Bimekizumab Over 4 Years Highlighted in Psoriasis 

This iteration of the ‘Month in Review’ series highlights top headlines covered in April in dermatology news, including FDA decisions.

7 Dermatology Headlines You Missed in April 2026

Are IL-23 inhibitors, rather than IL-17 inhibitors, the preferred biologic for psoriasis patients at risk of developing psoriatic arthritis?

IL-23 or IL-17 for Preventing Psoriasis Progression into PsA, With Andrew Blauvelt, MD, MBA

This Q&A interview with Nambudiri covers the AAD Clinical Image Collection, launched in January 2025 to address diversity in dermatology education.



Q&A: How Dermatologists Can Utilize the AAD Clinical Image Collection, With Vinod Nambudiri, MD, MBA, MPH

In this Q&A interview, Bhatia discusses the FDA's recent acceptance of BLA for imsidolimab for generalized pustular psoriasis (GPP).

Q&A: Discussing Imsidolimab for Generalized Pustular Psoriasis, With Neal Bhatia, MD

These Week 16, phase 2a findings from the EVERLAST-A study assessing ORKA-001 highlight the treatment's potential in those with plaque psoriasis.

EVERLAST-A: Positive Phase 2a Data Observed for ORKA-001 in Psoriasis at Week 16

Armstrong spoke in an interview regarding several different sessions presented at the 2026 AAD meeting.

Q&A: IL-23, Oral Therapies, and Inflammatory Disease Management, With April W. Armstrong, MD, MPH

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Plaque Psoriasis